Want to see HK:2161 full AI Analyst Report?
2161 Stock Chart & Stats
HK$1.97
HK$0.00(0.00%)
At close: 4:00 PM EDT
HK$1.97
HK$0.00(0.00%)
Day’s Range― - ―
52-Week RangeHK$1.84 - HK$3.19
Previous CloseN/A
Volume140.00K
Average Volume (3M)599.79K
Market Cap
HK$1.58B
Enterprise ValueHK$2.49K
Total Cash (Recent Filing)HK$119.94M
Total Debt (Recent Filing)HK$393.72M
Price to Earnings (P/E)7.7
Beta0.16
Next Earnings
Nov 20, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield11.07%
Share Statistics
EPS (TTM)0.25
Shares Outstanding822,000,000
10 Day Avg. Volume515,131
30 Day Avg. Volume599,792
Financial Highlights & Ratios
PEG Ratio2.55
Price to Book (P/B)2.01
Price to Sales (P/S)2.60
P/FCF Ratio18.20
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.26
Revenue Forecast (FY)HK$935.78M
Bulls Say, Bears Say
Bulls Say
Revenue GrowthMaterial top-line scaling over 2021–2026 demonstrates durable demand and a scalable business model. Sustained revenue expansion supports fixed-cost absorption, funds R&D and commercial investment, and underpins multi-period earnings visibility and long-term market share gains.
Margin ExpansionLarge gross and net margin improvement reflects structural gains from scale, product mix and operating leverage. Higher sustainable margins improve cash generation potential and return on capital, providing flexibility to invest, defend pricing, and withstand cyclical pressures over coming quarters.
Balance Sheet & ROEA sizable equity base with improving ROE signals better capital efficiency and a buffer for growth investments. Historically low leverage before 2026 provided financial flexibility; the strong equity cushion helps absorb shocks and supports strategic initiatives without immediate refinancing pressure.
Bears Say
Rising LeverageThe notable 2026 jump in debt reduces financial flexibility relative to earlier years and raises interest cost sensitivity. If growth slows or margins compress, higher leverage could constrain capital allocation, elevate refinancing risk, and limit ability to pursue opportunistic investments over the medium term.
Free Cash Flow DeclineA sharp FCF drop and missing conversion metrics weaken confidence in cash generation sustainability. This may reflect higher capex or working-capital strain; reduced cash conversion undermines the company’s ability to delever, fund dividends, or finance organic expansion without adding more debt.
Margin Sustainability RiskAfter rapid margin expansion, a year-over-year easing suggests part of earlier gains may be cyclical or non-recurring. Maintaining very high gross/net margins will require ongoing cost discipline, favorable product mix and pricing power; any reversal would materially affect earnings durability.
JBM (Healthcare) Ltd. News
2161 FAQ
What was JBM (Healthcare) Ltd.’s price range in the past 12 months?
JBM (Healthcare) Ltd. lowest stock price was HK$1.84 and its highest was HK$3.19 in the past 12 months.
What is JBM (Healthcare) Ltd.’s market cap?
JBM (Healthcare) Ltd.’s market cap is HK$1.58B.
When is JBM (Healthcare) Ltd.’s upcoming earnings report date?
JBM (Healthcare) Ltd.’s upcoming earnings report date is Nov 20, 2026 which is in 111 days.
How were JBM (Healthcare) Ltd.’s earnings last quarter?
JBM (Healthcare) Ltd. released its earnings results on Jun 22, 2026. The company reported HK$0.106 earnings per share for the quarter, beating the consensus estimate of N/A by HK$0.106.
Is JBM (Healthcare) Ltd. overvalued?
According to Wall Street analysts JBM (Healthcare) Ltd.’s price is currently Overvalued.
Does JBM (Healthcare) Ltd. pay dividends?
JBM (Healthcare) Ltd. pays a Semiannually dividend of HK$0.073 which represents an annual dividend yield of 11.07%. See more information on JBM (Healthcare) Ltd. dividends here
What is JBM (Healthcare) Ltd.’s EPS estimate?
JBM (Healthcare) Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does JBM (Healthcare) Ltd. have?
JBM (Healthcare) Ltd. has 822,000,000 shares outstanding.
What happened to JBM (Healthcare) Ltd.’s price movement after its last earnings report?
JBM (Healthcare) Ltd. reported an EPS of HK$0.106 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -0.437%.
Which hedge fund is a major shareholder of JBM (Healthcare) Ltd.?
Currently, no hedge funds are holding shares in HK:2161
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
JBM (Healthcare) Ltd. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
218.77%
12-Months-Change
Fundamentals
Return on Equity
11.07%
Trailing 12-Months
Asset Growth
14.08%
Trailing 12-Months
Company Description
JBM (Healthcare) Ltd.
JBM (Healthcare) Limited functions as an investment holding company that operates across Asia, engaging in the entire process of bringing healthcare and wellness products to market, from their conception and production to their promotion, distribution, and ultimate sale. The firm's offerings include a diverse range of consumer health products, such as its own branded traditional Chinese medicines – spanning everything from over-the-counter medications to specific medicated and non-medicated treatments. Additionally, it supplies diagnostic equipment and various pharmaceutical goods. Beyond manufacturing, JBM (Healthcare) is also involved in the buying, selling, and reselling (wholesale and retail) of Chinese medicines. Its business activities extend to the trade of medical supplies and pharmaceuticals, as well as the sale of general health and herbal products. Established in 2020, the company's main operations are directed from its headquarters in Kwun Tong, Hong Kong. JBM (Healthcare) Limited is a subsidiary entity of JBM Group (BVI) Limited.
Technical Analysis
Lee's Pharmaceutical Holdings Limited
―
Dawnrays Pharmaceutical Holdings Ltd.
―
Pak Fah Yeow International Limited
―
Jacobson Pharma Corporation Limited
―
VISEN Pharmaceuticals
―